Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32462-32477

  Guillem Llobat, Paloma ^a   Dovizio, Melania ^a   Bruno, Annalisa ^a   Ricciotti, Emanuela ^b   Cufino, Valerio ^c   Sacco, Angela ^a   Grande, Rosalia ^a   Alberti, Sara ^a   Arena, Vincenzo ^c   Cirillo, Mariangela ^c   Patrono, Carlo ^c   FitzGerald, Garret A ^b   Steinhilber, Dieter ^d   Sgambato, Alessandro ^c   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Aspirin; Colorectal cancer; Epithelial mesenchymal transition; Metastasis; Platelets

Indexed keywords

3 [1 (2,4 DICHLOROBENZYL) 5 FLUORO 3 METHYL 1H INDOL 7 YL] N [(4,5 DICHLORO 2 THIENYL)SULFONYL]ACRYLAMIDE; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CYCLOOXYGENASE 1; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; PROTEIN TWIST1; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; TICAGRELOR; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CELL INTERACTION; CELL MOTILITY; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MESENCHYME CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TUMOR CELL; UPREGULATION; ANIMAL; BLOOD; CELL COMMUNICATION; CELL MOTION; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; HT-29 CELL LINE; METASTASIS; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; THROMBOCYTE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CELL COMMUNICATION; CELL MOVEMENT; COLORECTAL NEOPLASMS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; HETEROGRAFTS; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; TUMOR CELLS, CULTURED;

EID: 84973542336     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8655     Document Type: Article

References (32)

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-273.
3. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237-249.
4. Labelle M, Begum S, Hynes RO. Direct signalling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576-590.
5. Dovizio M, Maier TJ, Alberti S, Di Francesco L, Marcantoni E, Münch G, John CM, Suess B, Sgambato A, Steinhilber D, Patrignani P. Pharmacological inhibition of platelet-tumorcell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol. 2013;84:25-40.
6. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123-134.
7. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379:1602-1612.
8. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-1601.
9. Meade TW, The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
10. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
11. Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124:184-187.
12. Michelson AD. Advances in antiplatelet therapy. Hematology Am SocHematolEduc Program. 2011;2011:62-69.
13. Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev. 2011;19:95-100.
14. Singh J, Zeller W, Zhou N, Hategen G, Mishra R, Polozov A, Yu P, Onua E, Zhang J, Zembower D, Kiselyov A, Ramírez JL, Sigthorsson G, et al. Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem Biol. 2009;4:115-126.
15. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res. 1987;47:647-656.
16. Menter DG, Dubois RN. Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol. 2012;2012:723419.
17. Wang D, DuBois RN. Urinary PGE-M: A Promising Cancer Biomarker. Cancer prevention research. 2013;6:507-510.
18. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659-661
19. Patrono C, Ciabattoni G, Pinca E,Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317-327.
20. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117:927-939.
21. Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367:235-241.
22. Hallinan EA, Hagen TJ, Tsymbalov S, Husa RK, Lee AC, Stapelfeld A, Savage MA. Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. J Med Chem. 1996; 39:609-613.
23. afForselles KJ, Root J, Clarke T,Davey D, Aughton K, Dack K, Pullen N. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol. 2011; 164:1847-1856.
24. Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuillet E, Nelson MA. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res. 2007;313:2969-2979.
25. Yang WH, Lan HY, Huang CH, Tai SK, Tzeng CH, Kao SY, Wu KJ, Hung MC, Yang MH. RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol. 2012;14:366-374.
26. Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest. 2001;107:603-610.
27. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115:3427-36.
28. Matsui Y, Amano H, Ito Y, Eshima K, Suzuki T, Ogawa F, Iyoda A, Satoh Y, Kato S, Nakamura M, Kitasato H, Narumiya S, Majima M. Thromboxane A2 receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells.Cancer Sci. 2012;103:700-707.
29. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, Honn KV. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun. 2000;267:245-251.
30. Sciulli MG, Filabozzi P, Tacconelli S, Padovano R, Ricciotti E, Capone ML, Grana M, Carnevale V, Patrignani P. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids. 2005;72:79-83.
31. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. NOD/SCID/γc null mouse: An excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175-3182.
32. Song WL, Lawson JA, Wang M, Zou H, FitzGerald GA. Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol. 2007;433:51-72.